What to verify when reading public information on CAR T-cell therapy

CAR T is not a universal cancer treatment. Suitability depends on product, cancer type, therapy line and patient status.

Treatment generally requires experienced centers with appropriate support capacity.

The process may involve cell collection, manufacturing, conditioning therapy, inpatient monitoring and adverse-event management.

Cross-border inquiry should include waiting time, fees, caregiver needs and follow-up.